{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:38:59Z","timestamp":1772210339347,"version":"3.50.1"},"reference-count":57,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Rearranged during transfection (RET) is an oncogenic driver receptor that is overexpressed in several cancer types, including non-small cell lung cancer. To date, only multiple kinase inhibitors are widely used to treat RET-positive cancer patients. These inhibitors exhibit high toxicity, less efficacy, and specificity against RET. The development of drug-resistant mutations in RET protein further deteriorates this situation. Hence, in the present study, we aimed to design novel drug-like compounds using a fragment-based drug designing strategy to overcome these issues. About 18 known inhibitors from diverse chemical classes were fragmented and bred to form novel compounds against RET proteins. The inhibitory activity of the resultant 115 hybrid molecules was evaluated using molecular docking and RF-Score analysis. The binding free energy and chemical reactivity of the compounds were computed using MM-GBSA and density functional theory analysis, respectively. The results from our study revealed that the developed hybrid molecules except for LF21 and LF27 showed higher reactivity and stability than Pralsetinib. Ultimately, the process resulted in three hybrid molecules namely LF1, LF2, and LF88 having potent inhibitory activity against RET proteins. The scrutinized molecules were then subjected to molecular dynamics simulation for 200 ns and MM-PBSA analysis to eliminate a false positive design. The results from our analysis hypothesized that the designed compounds exhibited significant inhibitory activity against multiple RET variants. Thus, these could be considered as potential leads for further experimental studies.<\/jats:p>","DOI":"10.3390\/molecules27051590","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T20:11:14Z","timestamp":1646079074000},"page":"1590","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Designing Novel Compounds for the Treatment and Management of RET-Positive Non-Small Cell Lung Cancer\u2014Fragment Based Drug Design Strategy"],"prefix":"10.3390","volume":"27","author":[{"given":"Priyanka","family":"Ramesh","sequence":"first","affiliation":[{"name":"Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore 632014, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthi","family":"Veerappapillai","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore 632014, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.semcancer.2020.02.009","article-title":"Applications and strategies in nanodiagnosis and nanotherapy in lung cancer","volume":"69","author":"Woodman","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cascetta, P., Sforza, V., Manzo, A., Carillio, G., Palumbo, G., Esposito, G., Montanino, A., Costanzo, R., Sandomenico, C., and De Cecio, R. (2021). RET Inhibitors in Non-Small-Cell Lung Cancer. Cancers, 13.","DOI":"10.3390\/cancers13174415"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Fancelli, S., Caliman, E., Mazzoni, F., Brugia, M., Castiglione, F., Voltolini, L., Pillozzi, S., and Antonuzzo, L. (2021). Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13051091"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01025-7","article-title":"Therapeutic strategies in RET gene rearranged non-small cell lung cancer","volume":"14","author":"Drusbosky","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: Lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2159-8290.CD-18-0839","article-title":"A Phase I\/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105","volume":"9","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_10","first-page":"3504","article-title":"Drug resistance profiles of mutations in the RET kinase domain","volume":"175","author":"Liu","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/s12248-018-0216-7","article-title":"Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications","volume":"20","author":"Bian","year":"2018","journal-title":"AAPS J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1039\/D1RA07328A","article-title":"Investigating natural compounds against oncogenic RET tyrosine kinase using pharmacoinformatic approaches for cancer therapeutics","volume":"12","author":"Parate","year":"2021","journal-title":"RSC Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1900053","DOI":"10.1002\/ardp.201900053","article-title":"Quinazoline based 1,3,5-triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: Design, synthesis, docking, and QSAR study","volume":"352","author":"Pathak","year":"2019","journal-title":"Arch. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"584894","DOI":"10.3389\/fchem.2020.584894","article-title":"Identification of a New Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations","volume":"8","author":"Shoun","year":"2020","journal-title":"Front. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fmolb.2020.00180","article-title":"Application of Fragment-Based Drug Discovery to Versatile Targets","volume":"7","author":"Li","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5530\/ijper.54.1.14","article-title":"Design of ALK Inhibitors for Non-Small Cell Lung Cancer\u2013A Fragment Based Approach","volume":"54","author":"Jain","year":"2020","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Alkaff, A.H., Saragih, M., Imana, S.N., Nasution, M.A.F., and Tambunan, U.S.F. (2021). Identification of DNA Methyltransferase-1 Inhibitor for Breast Cancer Therapy through Computational Fragment-Based Drug Design. Molecules, 26.","DOI":"10.3390\/molecules26020375"},{"key":"ref_18","first-page":"352","article-title":"Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update","volume":"12","author":"Mendoza","year":"2018","journal-title":"Oncol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and Translational Implications of RET Rearrangements in Non\u2013Small Cell Lung Cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A Major Update to the DrugBank Database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","article-title":"PubChem substance and compound databases","volume":"44","author":"Kim","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33577","DOI":"10.1074\/jbc.M605604200","article-title":"Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain","volume":"281","author":"Knowles","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/j.ejmech.2011.03.035","article-title":"Potential virtual lead identification in the discovery of renin inhibitors: Application of ligand and structure-based pharmacophore modeling approaches","volume":"46","author":"Thangapandian","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1080\/07391102.2020.1771424","article-title":"Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease","volume":"39","author":"Choudhury","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision Targeted Therapy with BLU-667 for RET-Driven Cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/1078-0432.CCR-21-0967","article-title":"FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.str.2019.05.012","article-title":"Continuous Evaluation of Ligand Protein Predictions: A Weekly Community Challenge for Drug Docking","volume":"27","author":"Wagner","year":"2019","journal-title":"Structure"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83142","DOI":"10.18632\/oncotarget.20915","article-title":"Virtual screening approach to identifying influenza virus neuraminidase inhibitors using molecular docking combined with machine-learning-based scoring function","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/10799893.2019.1660895","article-title":"High-throughput virtual screening, ADME analysis, and estimation of MM\/GBSA binding-free energies of azoles as potential inhibitors of Mycobacterium tuberculosis H37Rv","volume":"39","author":"Madhavaram","year":"2019","journal-title":"J. Recept. Signal Transduct."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00894-019-4238-6","article-title":"Computer-aided identification of lead compounds as Staphylococcal epidermidis FtsZ inhibitors using molecular docking, virtual screening, DFT analysis, and molecular dynamic simulation","volume":"25","author":"Tripathy","year":"2019","journal-title":"J. Mol. Model."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"130880","DOI":"10.1016\/j.molstruc.2021.130880","article-title":"Synthesis, spectra (FT-IR, NMR) investigations, DFT study, in silico ADMET and Molecular docking analysis of 2-amino-4-(4-aminophenyl)thiophene-3-carbonitrile as a potential anti-tubercular agent","volume":"1244","author":"Obu","year":"2021","journal-title":"J. Mol. Struct."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"07544","DOI":"10.1016\/j.heliyon.2021.e07544","article-title":"Investigation on electronic structure, vibrational spectra, NBO analysis, and molecular docking studies of aflatoxins and selected emerging mycotoxins against wild-type androgen receptor","volume":"7","author":"Agwupuye","year":"2021","journal-title":"Heliyon"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s00044-016-1591-1","article-title":"Identification of novel natural compound inhibitors for human complement component 5a receptor by homology modeling and virtual screening","volume":"25","author":"Shaikh","year":"2016","journal-title":"Med. Chem. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1080\/07391102.2017.1341337","article-title":"Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase","volume":"36","author":"Shukla","year":"2018","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/08927022.2019.1662002","article-title":"Molecular docking and simulation analysis for elucidation of toxic effects of dicyclohexyl phthalate (DCHP) in glucocorticoid receptor-mediated adipogenesis","volume":"46","author":"Singh","year":"2020","journal-title":"Mol. Simul."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"W502","DOI":"10.1093\/nar\/gkaa327","article-title":"PaccMann: A web service for interpretable anticancer compound sensitivity prediction","volume":"48","author":"Cadow","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/07391102.2020.1711809","article-title":"Identification of a novel binding mechanism of Quinoline based molecules with lactate dehydrogenase of Plasmodium falciparum","volume":"39","author":"Singh","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1080\/07391102.2020.1752802","article-title":"Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19","volume":"39","author":"Muralidharan","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s10822-018-0160-8","article-title":"In silico fragment-mapping method: A new tool for fragment-based\/structure-based drug discovery","volume":"32","author":"Yamaotsu","year":"2018","journal-title":"J. Comput. Mol. Des."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/ci400534h","article-title":"Implementation of the Hungarian Algorithm to Account for Ligand Symmetry and Similarity in Structure-Based Design","volume":"54","author":"Allen","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1021\/acs.jcim.0c00545","article-title":"Fast Rescoring Protocols to Improve the Performance of Structure-Based Virtual Screening Performed on Protein\u2013Protein Interfaces","volume":"60","author":"Singh","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/cbic.201600654","article-title":"Development of an Efficient G-Quadruplex-Stabilised Thrombin-Binding Aptamer Containing a Three-Carbon Spacer Molecule","volume":"18","author":"Aaldering","year":"2017","journal-title":"ChemBioChem"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.procbio.2019.04.018","article-title":"Identification of novel inhibitors of signal transducer and activator of transcription 3 over signal transducer and activator of transcription 1 for the treatment of breast cancer by in-silico and in-vitro approach","volume":"82","author":"Palaka","year":"2019","journal-title":"Process Biochem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4155\/fmc-2020-0170","article-title":"Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders","volume":"13","author":"Jia","year":"2021","journal-title":"Future Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Al-Majid, A.M., Islam, M.S., Atef, S., El-Senduny, F.F., Badria, F.A., Elshaier, Y.A.M.M., Ali, M., Barakat, A., and Rahman, A.F.M.M. (2019). Synthesis of Pyridine-Dicarboxamide-Cyclohexanone Derivatives: Anticancer and \u03b1-Glucosidase Inhibitory Activities and In Silico Study. Molecules, 24.","DOI":"10.3390\/molecules24071332"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1039\/C7OB01384A","article-title":"A facile I2-catalyzed synthesis of imidazo[1,2-a]pyridines via sp3 C\u2013H functionalization of azaarenes and evaluation of anticancer activity","volume":"15","author":"Mani","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"W257","DOI":"10.1093\/nar\/gky318","article-title":"ProTox-II: A webserver for the prediction of toxicity of chemicals","volume":"46","author":"Banerjee","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1021\/acs.jcim.0c00057","article-title":"Improving Protein-Ligand Docking Results with High-Throughput Molecular Dynamics Simulations","volume":"60","author":"Guterres","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/07391102.2018.1444509","article-title":"A novel identification approach for discovery of 5-HydroxyTriptamine 2A antagonists: Combination of 2D\/3D similarity screening, molecular docking and molecular dynamics","volume":"37","author":"Kumar","year":"2018","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Londhe, A.M., Gadhe, C.G., Lim, S.M., and Pae, A.N. (2019). Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques. Molecules, 24.","DOI":"10.3390\/molecules24224085"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jmgm.2017.04.026","article-title":"Structural and functional effects of nucleotide variation on the human TB drug metabolizing enzyme arylamine N -acetyltransferase 1","volume":"75","author":"Cloete","year":"2017","journal-title":"J. Mol. Graph. Model."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1021\/acs.jcim.7b00347","article-title":"Statistical Analysis on the Performance of Molecular Mechanics Poisson\u2013Boltzmann Surface Area versus Absolute Binding Free Energy Calculations: Bromodomains as a Case Study","volume":"57","author":"Aldeghi","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/ci400628q","article-title":"Virtual Screening of PRK1 Inhibitors: Ensemble Docking, Rescoring Using Binding Free Energy Calculation and QSAR Model Development","volume":"54","author":"Slynko","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1021\/acs.molpharmaceut.9b00520","article-title":"Toward Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-Based Convolutional Encoders","volume":"16","author":"Manica","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10238-019-00587-2","article-title":"Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells","volume":"20","author":"Tabata","year":"2019","journal-title":"Clin. Exp. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"107438","DOI":"10.1016\/j.pharmthera.2019.107438","article-title":"Drug resistance to targeted therapeutic strategies in non-small cell lung cancer","volume":"206","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/5\/1590\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:29:14Z","timestamp":1760135354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/5\/1590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["molecules27051590"],"URL":"https:\/\/doi.org\/10.3390\/molecules27051590","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}